Sales & Marketing

Following a five-year legal battle between Boston Scientific and TissueGen, Boston Scientific has had to pay $42m

Garuda Therapeutics has announced that it has closed series B funding with $62m

AbbVie has announced that it expects a 37% decline in sales of Humira following the approval of biosimilars

After a pivotal few years, Moderna has agreed its first acquisition, worth $85m, which will allow the company access to cell-free DNA synthesis and amplification technologies. Moderna is set to acquire OriCiro Genomics K.K., gaining its expertise in DNA synthesis and amplification.

AstraZeneca has announced that it is set to acquire the clinical-stage biopharmaceutical company CinCor in a deal worth up to $1.8bn.

With many pharma companies preparing for President Joe Biden’s Inflation Reduction Act (IRA) to begin having an impact, and inflation continuing to soar, the cost of at least 350 drugs is expected to rise in the US throughout 2023.

AstraZeneca announces acquisition of Neogene

Simiens Healthineers and Atrium Health announce partnership deal

Focus-X Therapeutics develops targeted radiopharmaceuticals to treat cancer, based on proprietary peptide engineering technology. This technology involves peptide radioliglands which precisely deliver alpha or beta emitters to break down cancer cell DNA. It allows for high-quality optimisation of peptide radioligland vectors for key pharmaceutical attributes such as biodistribution, binding affinity, and in vivo stability.

A collaboration effort has been agreed between Merck Research Laboratories (MSD) and Orna Therapeutics to discover, develop, and commercialise programmes of engineered circular (oRNA) therapies, in areas including infectious diseases and oncology.

Global Blood Therapeutics (GBT), a rare disease pharmaceutical company, has been bought by Pfizer for $5.4 billion in cash. The purchase will give Pfizer ownership of Oxbryta, a sickle cell disease-fighting drug which generated $195 million in 2021, with Pfizer expecting an increase in profits when it’s introduced to the global market.

US-based Kelai Pharmaceutical has hired Canada-based full service contract research organisation (CRO), Nutrasource Pharmaceutical and Nutraceutical Providers, to assist with their early stage drug growth programme, where they hope to establish drug candidates from botanical crops to develop prescribed drugs.